Demographic and disease-related variables of patients.
| DAS28-ESR Remission, n = 87 | Boolean Remission, n = 32 | Boolean Nonremission, n = 55 | p* | |
|---|---|---|---|---|
| Female, n (%) | 57 (66) | 22 (68.8) | 35 (63.6) | 0.62 |
| Age, yrs, mean ± SD | 50.52 ± 1.23 | 50.93 ± 1.32 | 50.29 ± 1.18 | 0.81 |
| RA duration, yrs, mean ± SD | 11.06 ± 7.93 | 11.40 ± 8.09 | 10.87 ± 7.9 | 0.76 |
| HAQ, mean ± SD | 0.33 ± 0.43 | 0.24 ± 0.52 | 0.39 ± 0.36 | 0.141 |
| TJC28, mean ± SD | 0 ± 0.5 | 0 ± 0.2 | 0 ± 0.6 | 0.233 |
| SJC28, mean ± SD | 0 ± 0.9 | 0 ± 0.3 | 0 ± 1.1 | 0.807 |
| ESR, mm/h, mean ± SD | 13.95 ± 8.11 | 15.37 ± 8.32 | 13.07 ± 7.87 | 0.201 |
| Anti-CCP positivity, n (%) | 46 (52.7) | 22 (66.8) | 26 (47.3) | 0.05 |
| RF positivity, n (%) | 58 (66.7) | 23 (71.9) | 35 (63.6) | 0.432 |
| VAS pain, mean ± SD | 2.04 ± 1.94 | 0.56 ± 0.94 | 2.9 ± 1.85 | 0.000 |
| PtGA, mean ± SD | 1.93 ± 1.80 | 0.46 ± 0.84 | 2.79 ± 1.65 | 0.000 |
| PGA, mean ± SD | 0.85 ± 0.82 | 0.53 ± 0.71 | 1.03 ± 0.83 | 0.005 |
| Steroid, n (%)a | 33 (26.4) | 8 (25) | 25 (45.5) | 0.05 |
| DMARD, n (%)a | 83 (95.4) | 30 (93.8) | 54 (98.2) | 0.275 |
| DMARD1, n (%)a | 69 (79.3) | 25 (78.1) | 45 (81.8) | 0.675 |
| DMARD2, n (%)a | 48 (55.2) | 15 (46.9) | 33 (60) | 0.235 |
| Biologic, n (%)a | 33 (37.9) | 9 (28.1) | 14 (25.5) | 0.785 |
↵a Current treatment;
↵* remission vs nonremission. DAS28: 28-joint count Disease Activity Score; ESR: erythrocyte sedimentation rate; RA: rheumatoid arthritis; HAQ: Health Assessment Questionnaire; TJC28: 28-joint tender joint count; SJC28: 28-joint swollen joint count; anti-CCP: anticyclic citrullinated peptide antibodies; RF: rheumatoid factor; VAS: visual analog scale; PtGA: patient’s global assessment; PGA: physician’s global assessment; DMARD: disease-modifying antirheumatic drug; DMARD1: methotrexate, leflunomide; DMARD2: sulfasalazine, hydroxychloroquine.